CEL-SCI CORP (CVM)

These stocks are moving in today's after hours session

Stay updated with the stocks that are on the move in today's after-hours session.

CEL-SCI Highlights Biological Rationale for the Use of Multikine in the Confirmatory Registration Head and Neck Cancer Study

U.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025

FDA’s Oncologic Drugs Advisory Committee Decision on Checkpoint Inhibitors Substantiates Potential of CEL-SCI’s Multikine® to Address Major Treatment Gap for PD-L1 Negative Cancer Patients

CEL-SCI Selects Ergomed as CRO as it Gears Up for Confirmatory FDA Registration Study of Multikine® in Head and Neck Cancer

CEL-SCI’s Multikine® Increased 5-Year Survival Rate to 82.6% in Locally Advanced Resectable Head & Neck Cancer Patients Who Were Deemed to be in the Treatment Group for Surgery and Radiation

CEL-SCI to Present New Data for Multikine® Head & Neck Cancer Immunotherapy at the European Society for Medical Oncology 2024 Congress

The UK’s Medicines & Healthcare Products Regulatory Agency Grants CEL-SCI a Pediatric Waiver, Bringing Multikine® One Step Closer to Future Marketing Clearance

CVM Stock Earnings: CEL-SCI Misses EPS for Q3 2024

CVM stock results show that CEL-SCI missed analyst estimates for earnings per share the third quarter of 2024.

CEL-SCI Corporation Reports Third Quarter Fiscal 2024 Financial Results

CEL-SCI Announces Closing of $10.8 Million Offering

CEL-SCI Announces Pricing of $10.8 Million Offering

CEL-SCI’s Phase 3 Population Analysis for Upcoming Confirmatory Registration Study in Head & Neck Cancer Demonstrates Well Balanced Patient Population, Confidence in Clinical Results

CEL-SCI Appoints Robert Watson as Chairperson of the Board

CEL-SCI Presents Head & Neck Cancer Data at Iddst Annual Congress in Budapest: Risk of Death Cut in Half for Patients Treated With Multikine in the Target Population

Dr. Giovanni Selvaggi, Who Has Brought Several Oncology Drugs to Market, Joins CEL-SCI as Clinical Advisor

CVM Stock Earnings: CEL-SCI Reported Results for Q2 2024

CEL-SCI just reported results for the second quarter of 2024.

CEL-SCI Corporation Reports Second Quarter Fiscal 2024 Financial Results

CEL-SCI Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head & Neck Cancer

CEL-SCI Appoints Mario Gobbo to Its Board of Directors

CEL-SCI’s LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in Immunology

CEL-SCI Corporation Issues Letter to Shareholders

CEL-SCI Corporation Reports First Quarter Fiscal 2024 Financial Results

CEL-SCI Announces Closing of $7.75 Million Public Offering of Common Stock

CEL-SCI stock falls as it prices its offering to raise $7.75M (NYSE:CVM)

CEL-SCI stock falls 22.81% in pre-market trade after pricing its offering of 3.88M shares at $2 per share, with gross proceeds of $7.75M.

CEL-SCI Announces Pricing of $7.75 Million Public Offering of Common Stock

CEL-SCI Completes Commissioning of Its Multikine Manufacturing Facility for Commercial Scale Production of Head & Neck Cancer Drug

European Medicines Agency Grants CEL-SCI a Waiver of Strict Pediatric Requirements, Clearing the Path Towards Marketing Authorization for Multikine®

CVM Stock Earnings: CEL-SCI Reported Results for Q4 2023

CEL-SCI just reported results for the fourth quarter of 2023.

CEL-SCI Reports Fiscal 2023 Financial Results and Clinical & Corporate Developments

UK’S National Institute for Health and Care Excellence (NICE) Selects CEL-SCI’s Multikine as Potential New Standard of Care for Head & Neck Cancer